Abiprubart Biosimilar - Research Grade

Human

CD40

>1mg/ml

IgG4 - kappa

CHO Cells

Anti-Mouse CD40 (FGK4.5) In Vivo Antibody - Low Endotoxin (ICH1073), Bulk Anti-Human CD40 (G28.5) Antibody (ICH1156), Dacetuzumab Biosimilar - Research Grade (ICH5030), Sotigalimab Biosimilar - Research Grade (ICH5031), Selicrelumab Biosimilar - Research Grade (ICH5032), Lucatumumab Biosimilar - Research Grade (ICH5129), Bleselumab Biosimilar - Research Grade (ICH5407), Cifurtilimab Biosimilar - Research Grade (ICH5437), Dalnicastobart Biosimilar - Research Grade (ICH5462), Giloralimab Biosimilar - Research Grade (ICH5571), Iscalimab Biosimilar - Research Grade (ICH5610), Mitazalimab Biosimilar - Research Grade (ICH5689), Ravagalimab Biosimilar - Research Grade (ICH5806), Teneliximab Biosimilar - Research Grade (ICH5915)

https://www.imgt.org/mAb-DB/

ICH3002

P25942

Blue ice

ICH5323 is a research-grade biosimilar of abiprubart (also known as KPL-404), supplied as an unconjugated, non-therapeutic analog built around the CD40 target. It is a humanized IgG4-kappa antibody matching the originator's format, in which the IgG4 backbone provides a functionally attenuated Fc so that binding blocks CD40 signaling without driving effector-mediated cell killing. The originator abiprubart is an investigational immunomodulator being developed to interrupt the CD40-CD154 (CD40 ligand) costimulatory axis, and has been evaluated in autoimmune indications including rheumatoid arthritis and Sjogren's disease. This product is intended for research use only and is not for human or clinical use. It is manufactured to in-vivo research standards with low endotoxin (research grade less than 1 EU/mg; ultra-low grade less than 0.5 EU/mg), and is available in bulk milligram-to-gram quantities suitable for larger studies. It is a useful reference reagent for assay development, binding and blocking studies, and as a benchmark control when characterizing anti-CD40 candidates targeting the same costimulatory pathway. CD40 (UniProt P25942) is a type I transmembrane receptor of the TNF receptor superfamily, expressed on B cells, dendritic cells, macrophages, and other antigen-presenting cells, as well as some non-immune cells. Its ligand, CD40L (CD154), is expressed mainly on activated CD4+ T cells. Engagement of CD40 by CD154 delivers a central costimulatory signal that drives B-cell activation, germinal center formation, immunoglobulin class switching, and affinity maturation, and licenses dendritic cells to prime T-cell responses. Because this axis is pivotal to humoral and Type 1 immunity, blocking CD40-CD154 interaction is an attractive strategy for suppressing pathogenic autoantibody production and T-cell-dependent inflammation in autoimmune disease, while a non-depleting, effector-silent format aims to modulate signaling without destroying the CD40-expressing cells.

CD40, Bp50, CDW40, TNFRSF5, p50, CD40 (protein), CD40 molecule

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks